NASDAQ:ACRX

AcelRx Pharmaceuticals - ACRX Stock Forecast, Price & News

$0.27

-0.04 (-12.90%)

(As of 08/12/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.26
▼
$0.28
50-Day Range: $0.18
▼
$0.35
52-Week Range: $0.16
▼
$1.20

Volume: 5.69 million shs
Average Volume: 3.49 million shs
Market Capitalization: $39.72 million

P/E Ratio: 0.93
Dividend Yield: N/A
Price Target: $5.00

AcelRx Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 1,751.9% Upside
$5.00 Price Target
Short Interest: Bearish
8.15% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.41
Upright™ Environmental Score
News Sentiment: 0.81
Based on 14 Articles This Week
Insider Trading: Acquiring Shares
$10,208 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.23) to ($0.15) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

257th out of 1,135 stocks

Pharmaceutical Preparations Industry

119th out of 557 stocks

3.3

Analyst's Opinion

Consensus Rating
AcelRx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.00, AcelRx Pharmaceuticals has a forecasted upside of 1,751.9% from its current price of $0.27.
Amount of Analyst Coverage
AcelRx Pharmaceuticals has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
8.15% of the outstanding shares of AcelRx Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
AcelRx Pharmaceuticals has a short interest ratio ("days to cover") of 5.6.
Change versus previous month
Short interest in AcelRx Pharmaceuticals has recently increased by 6.96%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
AcelRx Pharmaceuticals does not currently pay a dividend.
Dividend Growth
AcelRx Pharmaceuticals does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
AcelRx Pharmaceuticals has received a 53.29% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Sufentanil" and "Clinical research services for physiological diseases " products. See details.
Environmental Sustainability
The Environmental Impact score for AcelRx Pharmaceuticals is -2.41.

3.2

News and Social Media Coverage

News Sentiment
AcelRx Pharmaceuticals has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 14 news articles for AcelRx Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 16 people have searched for ACRX on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.
MarketBeat Follows
20 people have added AcelRx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 233% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AcelRx Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,208.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 5.50% of the stock of AcelRx Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 23.12% of the stock of AcelRx Pharmaceuticals is held by institutions.

1.9

Earnings and Valuation

Earnings Growth
Earnings for AcelRx Pharmaceuticals are expected to grow in the coming year, from ($0.23) to ($0.15) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AcelRx Pharmaceuticals is 0.93, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 121.76.
Price to Earnings Ratio vs. Sector
The P/E ratio of AcelRx Pharmaceuticals is 0.93, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 86.56.

See Top Rated MarketRank™ Stocks Here

About AcelRx Pharmaceuticals (NASDAQ:ACRX) Stock

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.

AcelRx Pharmaceuticals Stock Down 13.6 %

Shares of AcelRx Pharmaceuticals stock traded down $0.04 on Friday, hitting $0.27. 5,687,353 shares of the company were exchanged, compared to its average volume of 3,490,330. The company has a 50-day moving average price of $0.23 and a 200 day moving average price of $0.29. The stock has a market capitalization of $39.72 million, a price-to-earnings ratio of 0.93 and a beta of 0.44. AcelRx Pharmaceuticals has a 1-year low of $0.16 and a 1-year high of $1.20.

AcelRx Pharmaceuticals (NASDAQ:ACRX - Get Rating) last issued its earnings results on Thursday, August 11th. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.06). During the same period last year, the company earned ($0.08) earnings per share. Research analysts forecast that AcelRx Pharmaceuticals will post -0.23 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on shares of AcelRx Pharmaceuticals in a report on Tuesday. They set a "sell" rating for the company.

Receive ACRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACRX Stock News Headlines

August 12, 2022 | seekingalpha.com

AcelRx Pharma stock falls ~17% premarket after Q2 results, large runup in shares

August 12, 2022 | seekingalpha.com

AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q2 2022 Results - Earnings Call Transcript

August 11, 2022 | finance.yahoo.com

AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Misses Revenue Estimates

August 11, 2022 | finance.yahoo.com

AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at Plastic Surgery: The Meeting 2022

August 11, 2022 | finance.yahoo.com

AcelRx Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 10, 2022 | finance.yahoo.com

AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting

August 10, 2022 | americanbankingnews.com

AcelRx Pharmaceuticals (NASDAQ:ACRX) Research Coverage Started at StockNews.com

August 9, 2022 | americanbankingnews.com

AcelRx Pharmaceuticals (ACRX) to Release Earnings on Thursday

August 2, 2022 | americanbankingnews.com

AcelRx Pharmaceuticals (NASDAQ:ACRX) Earns Sell Rating from Analysts at StockNews.com

August 1, 2022 | americanbankingnews.com

Short Interest in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Increases By 81.4%

July 28, 2022 | finance.yahoo.com

AcelRx to Host Second Quarter 2022 Financial Results Call and Webcast on August 11, 2022

July 25, 2022 | americanbankingnews.com

AcelRx Pharmaceuticals (NASDAQ:ACRX) Receives New Coverage from Analysts at StockNews.com

July 8, 2022 | finance.yahoo.com

AcelRx Pharmaceuticals (NASDAQ:ACRX) shareholders are up 44% this past week, but still in the red over the last three years

May 19, 2022 | finance.yahoo.com

AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA®

May 19, 2022 | finance.yahoo.com

Why AcelRx Pharma Shares Are Trading Higher Today?

May 18, 2022 | seekingalpha.com

AcelRx Pharmaceuticals, Inc.'s (ACRX) CEO Vincent Angotti on Q1 2022 Results - Earnings Call Transcript

May 16, 2022 | seekingalpha.com

AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q1 2022 Results - Earnings Call Transcript

May 16, 2022 | finance.yahoo.com

AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 13, 2022 | finance.yahoo.com

Acutus Medical, Inc. (AFIB) Reports Q1 Loss, Tops Revenue Estimates

May 10, 2022 | finance.yahoo.com

AcelRx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (SST) Compared to Standard Intravenous Opioids during Plastic Surgery Procedures Performed under General Anesthesia

April 27, 2022 | finance.yahoo.com

AcelRx Hosting Key Opinion Leader Webinar on Niyad™ Nafamostat Program

April 21, 2022 | finance.yahoo.com

AcelRx Pharmaceuticals Announces Upcoming Podium Presentation on Use of DSUVIA® for Plastic Surgery Procedures at The Aesthetic Meeting 2022

March 31, 2022 | finance.yahoo.com

AcelRx Pharmaceuticals Announces Publication of Results from a Clinical Study Assessing Use of Sufentanil Sublingual Tablet for Painful Radiofrequency Microneedling Procedures

March 29, 2022 | finance.yahoo.com

AcelRx Pharmaceuticals Announces Publication of Clinical Data Finding Potential Benefits of Nafamostat Compared to Regional Citrate for Anticoagulation of the Dialysis Circuit

March 14, 2022 | seekingalpha.com

AcelRx stock falls 15% after HC Wainwright downgrade on 'disappointing quarter'

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ACRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACRX Company Calendar

Last Earnings: 8/11/2022
Today: 8/14/2022
Next Earnings (Estimated): 11/21/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ACRX
CUSIP: N/A
CIK: 1427925
Web: www.acelrx.com
Phone: (650) 216-3500
Fax: 650-216-6500
Employees: 43
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $5.00
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +1,751.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.29
Trailing P/E Ratio: 0.93
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-35,100,000.00
Net Margins: 1,588.91%
Pretax Margin: -1,266.35%
Return on Equity: N/A
Return on Assets: -45.18%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.51
Quick Ratio: 2.45

Sales & Book Value

Annual Sales: $2.82 million
Price / Sales: 14.09
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.30) per share
Price / Book: -0.90

Miscellaneous

Outstanding Shares: 147,110,000
Free Float: 139,023,000
Market Cap: $39.72 million
Optionable: Optionable
Beta: 0.44

Key Executives

Mr. Vincent J. Angotti (Age 54)
CEO & Director
Comp: $915.29k
Dr. Pamela Pierce Palmer M.D. (Age 59)
Ph.D., Co-Founder, Chief Medical Officer & Director
Comp: $682k
Mr. Raffi Mark Asadorian (Age 53)
Chief Financial Officer
Comp: $623.1k
Mr. Lawrence G. Hamel (Age 70)
Consultant
Mr. Anil N. Dasu (Age 59)
Chief Engineering Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ACRX Stock - Frequently Asked Questions

Should I buy or sell AcelRx Pharmaceuticals stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACRX shares.
View ACRX analyst ratings or view top-rated stocks.
What is AcelRx Pharmaceuticals' stock price forecast for 2022?: 2 brokerages have issued 1 year price targets for AcelRx Pharmaceuticals' stock. Their ACRX share price forecasts range from $5.00 to $5.00. On average, they predict the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 1,751.9% from the stock's current price.
View analysts price targets for ACRX or view top-rated stocks among Wall Street analysts.
How have ACRX shares performed in 2022?: AcelRx Pharmaceuticals' stock was trading at $0.56 at the beginning of 2022. Since then, ACRX shares have decreased by 51.8% and is now trading at $0.27.
View the best growth stocks for 2022 here.
When is AcelRx Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our ACRX earnings forecast.
How were AcelRx Pharmaceuticals' earnings last quarter?: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) posted its quarterly earnings results on Thursday, August, 11th. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). During the same quarter in the prior year, the company posted ($0.08) EPS.

What other stocks do shareholders of AcelRx Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), OPKO Health (OPK), CyberArk Software (CYBR), Flexion Therapeutics (FLXN) and NVIDIA (NVDA).
What is AcelRx Pharmaceuticals' stock symbol?: AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."
Who are AcelRx Pharmaceuticals' major shareholders?: AcelRx Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Values First Advisors Inc. (0.52%), Virtu Financial LLC (0.08%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adrian Adams, Mark G Edwards and Vincent J Angotti.
View institutional ownership trends.
How do I buy shares of AcelRx Pharmaceuticals?: Shares of ACRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is AcelRx Pharmaceuticals' stock price today?: One share of ACRX stock can currently be purchased for approximately $0.27.
How much money does AcelRx Pharmaceuticals make?: AcelRx Pharmaceuticals (NASDAQ:ACRX) has a market capitalization of $39.72 million and generates $2.82 million in revenue each year. The specialty pharmaceutical company earns $-35,100,000.00 in net income (profit) each year or $0.29 on an earnings per share basis.
How can I contact AcelRx Pharmaceuticals?: AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.acelrx.com. The specialty pharmaceutical company can be reached via phone at (650) 216-3500, via email at bkorb@troutgroup.com, or via fax at 650-216-6500.

This page (NASDAQ:ACRX) was last updated on 8/14/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

AcelRx Pharmaceuticals - ACRX Stock Forecast, Price & News

AcelRx Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About AcelRx Pharmaceuticals (NASDAQ:ACRX) Stock

AcelRx Pharmaceuticals Stock Down 13.6 %

Wall Street Analysts Forecast Growth

ACRX Stock News Headlines

ACRX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ACRX Stock - Frequently Asked Questions

Should I buy or sell AcelRx Pharmaceuticals stock right now?

What is AcelRx Pharmaceuticals' stock price forecast for 2022?

How have ACRX shares performed in 2022?

When is AcelRx Pharmaceuticals' next earnings date?

How were AcelRx Pharmaceuticals' earnings last quarter?

What other stocks do shareholders of AcelRx Pharmaceuticals own?

What is AcelRx Pharmaceuticals' stock symbol?

Who are AcelRx Pharmaceuticals' major shareholders?

How do I buy shares of AcelRx Pharmaceuticals?

What is AcelRx Pharmaceuticals' stock price today?

How much money does AcelRx Pharmaceuticals make?

How can I contact AcelRx Pharmaceuticals?

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™